Terms: = Lung cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
17 results:
1. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao MV; Araujo HA; Lamberti G; Cooper AJ; Akhave NS; Zhou T; Delasos L; Hicks JK; Aldea M; Minuti G; Hines J; Aredo JV; Dennis MJ; Chakrabarti T; Scott SC; Bironzo P; Scheffler M; Christopoulos P; Stenzinger A; Riess JW; Kim SY; Goldberg SB; Li M; Wang Q; Qing Y; Ni Y; Do MT; Lee R; Ricciuti B; Alessi JV; Wang J; Resuli B; Landi L; Tseng SC; Nishino M; Digumarthy SR; Rinsurongkawong W; Rinsurongkawong V; Vaporciyan AA; Blumenschein GR; Zhang J; Owen DH; Blakely CM; Mountzios G; Shu CA; Bestvina CM; Garassino MC; Marrone KA; Gray JE; Patel SP; Cummings AL; Wakelee HA; Wolf J; Scagliotti GV; Cappuzzo F; Barlesi F; Patil PD; Drusbosky L; Gibbons DL; Meric-Bernstam F; Lee JJ; Heymach JV; Hong DS; Heist RS; Awad MM; Skoulidis F
Cancer Discov; 2023 Jul; 13(7):1556-1571. PubMed ID: 37068173
[TBL] [Abstract] [Full Text] [Related]
2. Genetic variants in LKB1/AMPK/mtor pathway are associated with clinical outcomes of chemotherapy in non-small cell lung cancer.
Choi SH; Do SK; Lee SY; Choi JE; Kang HG; Hong MJ; Lee JH; Lee WK; Jeong JY; Shin KM; Do YW; Lee EB; Park JE; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
Thorac Cancer; 2022 Dec; 13(23):3322-3330. PubMed ID: 36239337
[TBL] [Abstract] [Full Text] [Related]
3. Relationship between the microRNAs and PI3K/AKT/mtor axis: Focus on non-small cell lung cancer.
Lin Y; Zhang L; Ding X; Chen C; Meng M; Ke Y; Wang W
Pathol Res Pract; 2022 Nov; 239():154093. PubMed ID: 36183437
[TBL] [Abstract] [Full Text] [Related]
4. The classification of neuroendocrine neoplasms of the lung and digestive system according to WHO, 5th edition: similarities, differences, challenges, and unmet needs.
Sanguedolce F; Zanelli M; Palicelli A; Cavazza A; DE Marco L; Zizzo M; Ascani S; Landriscina M; Giordano G; Sollitto F; Loizzi D
Panminerva Med; 2022 Jun; 64(2):259-264. PubMed ID: 35146989
[TBL] [Abstract] [Full Text] [Related]
5. Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells.
Yang Y; Neo SY; Chen Z; Cui W; Chen Y; Guo M; Wang Y; Xu H; Kurzay A; Alici E; Holmgren L; Haglund F; Wang K; Lundqvist A
J Clin Invest; 2020 Oct; 130(10):5508-5522. PubMed ID: 32673292
[TBL] [Abstract] [Full Text] [Related]
6. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
7. Elevated TRIP13 drives the AKT/mtor pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract] [Full Text] [Related]
8. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma.
Krencz I; Sebestyen A; Papay J; Lou Y; Lutz GF; Majewicz TL; Khoor A
Hum Pathol; 2019 Nov; 93():74-80. PubMed ID: 31454632
[TBL] [Abstract] [Full Text] [Related]
9. Interaction of Discoidin Domain Receptor 1 with a 14-3-3-Beclin-1-Akt1 Complex Modulates Glioblastoma Therapy Sensitivity.
Vehlow A; Klapproth E; Jin S; Hannen R; Hauswald M; Bartsch JW; Nimsky C; Temme A; Leitinger B; Cordes N
Cell Rep; 2019 Mar; 26(13):3672-3683.e7. PubMed ID: 30917320
[TBL] [Abstract] [Full Text] [Related]
10. The clinical outcome of recurrent sacral chordoma with further surgical treatment.
Yang Y; Li Y; Liu W; Xu H; Niu X
Medicine (Baltimore); 2018 Dec; 97(52):e13730. PubMed ID: 30593146
[TBL] [Abstract] [Full Text] [Related]
11. Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration.
Chebib N; Archer F; Bobet-Erny A; Leroux C; Cottin V
Sci Rep; 2018 Oct; 8(1):14698. PubMed ID: 30279475
[TBL] [Abstract] [Full Text] [Related]
12. iASPP facilitates tumor growth by promoting mtor-dependent autophagy in human non-small-cell lung cancer.
Xue Y; Han H; Wu L; Pan B; Dong B; Yin CC; Tian Z; Liu X; Yang Y; Zhang H; Chen Y; Chen J
Cell Death Dis; 2017 Oct; 8(10):e3150. PubMed ID: 29072696
[TBL] [Abstract] [Full Text] [Related]
13. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
[TBL] [Abstract] [Full Text] [Related]
14. Genetic variants in the PI3K/PTEN/AKT/mtor pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
[TBL] [Abstract] [Full Text] [Related]
15. Brief report: a phase II "window-of-opportunity" frontline study of the mtor inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.
Reungwetwattana T; Molina JR; Mandrekar SJ; Allen-Ziegler K; Rowland KM; Reuter NF; Luyun RF; Dy GK; Marks RS; Schild SE; Jett JR; Adjei AA
J Thorac Oncol; 2012 May; 7(5):919-22. PubMed ID: 22722792
[TBL] [Abstract] [Full Text] [Related]
16. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?
Fischer B; Marinov M; Arcaro A
Cancer Treat Rev; 2007 Jun; 33(4):391-406. PubMed ID: 17368733
[TBL] [Abstract] [Full Text] [Related]
17. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.
Lim WT; Zhang WH; Miller CR; Watters JW; Gao F; Viswanathan A; Govindan R; McLeod HL
Oncol Rep; 2007 Apr; 17(4):853-7. PubMed ID: 17342327
[TBL] [Abstract] [Full Text] [Related]
